Abstract 1235
Background
Uveal Melanoma (UVM) is the most common ocular malignancy. Many mutations were identified in affected patients defining genetic predisposition syndromes. Previous studies discussed separately the incidence of single or second primary ocular melanomas. However, understanding the genetic background, and relation to other tumors requires further investigation for defining the UVM subgroups, their shared developmental and, hence, the targeting mechanisms.
Methods
We used Surveillance Epidemiology and End Results program of the National Cancer Institute, United States, to review patients diagnosed with UVM, either as single primary or combined with other malignancies, between 1973 and 2015. We have calculated standardized incidence ratios (SIR) and measured risk in the form of Observed/Expected ratios (O/E) and Hazard Ratios (HR).
Results
We have identified 7,386 patients diagnosed with single primary UVM, besides 646 with UVM followed by another malignancy and 437 patients diagnosed with a primary UVM after other malignancies. SIR of developing another malignancy following UVM was significant and increased most within the first 5 years following UVM following choroid uveal melanoma (1.198, 95%CI=1.056-1.353). The risk of developing melanomas of the skin, thyroid cancers, and kidney cancers, increased significantly within the first 5 years following UVM, with SIRs (3.763, 95%CI=2.539-5.372), (3.158, 95%CI=1.270-6.506), and (2.618, 95%CI=1.465-4.317), respectively. SIR of developing a second UVM following another malignancy was significant between the 5th and 10th years following the first cancer diagnosis (O/E=1.204, 95% CI = 1.007-1.428), where the increase of UVM risk was highest among patients with primary prostate cancer (1.404, 95%CI=1.024-1.878) or leukemia (2.915, 95%CI=1.070-6.345). Cox models did not show a significant difference between the overall survival of single UVM and second UVM, but females showed better overall survival outcomes. In addition, Ciliary body tumors, and dark-skinned people were associated with worse survival outcomes.
Conclusions
The three groups of uveal melanoma showed different behaviors that may represent diverse underlying developmental mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract